Top Story

IV stem cell treatment safe, effective in patients with nonischemic HF

IV stem cell treatment safe, effective in patients with nonischemic HF
August 29, 2016

A single administration of IV allogeneic mesenchymal stem cells was safe and improved certain outcomes in patients with nonischemic HF with reduced ejection fraction, according to the results of a phase 2a study presented at the European Society of Cardiology Congress.

Previous studies of stem cell therapy for patients with HF “were largely suggestive of potential benefits,” but the therapies were injected into the patient’s coronary arteries or myocardium, so the researchers wanted to investigate whether an IV therapy might also work, presenter Javed Butler, MD, MPH, MBA, FACC, FAHA, FESC, said in an interview with Cardiology Today.

NHLBI releases new strategic vision

August 28, 2016
The NHLBI announced eight objectives as part of a new strategic vision that charts the course for research in heart, lung, blood and sleep disorders into the next…

NHLBI working group identifies knowledge gaps on role of microbiota in BP regulation

August 27, 2016
The NHLBI announced that it convened a working group to share current scientific knowledge on the role of microbiota in the regulation of BP. The working group…
In the Journals

Frailty status may predict mortality in older patients undergoing cardiac surgeries

August 26, 2016
Assessing frailty before major cardiac surgical procedures or minimally invasive cardiac surgery predicts mortality and functional decline, according to findings…
In the Journals

TAVR confers improved mortality vs. surgery for patients at intermediate risk or lower

August 26, 2016
A self-expanding transcatheter aortic valve replacement system outperformed surgical aortic valve replacement for survival in patients at lower risk for surgery…
More News Headlines »